Skip to content

Qure.ai

Enterprise Grade

Qure.ai provides FDA-cleared AI tools that help radiologists, pulmonologists, and emergency physicians detect lung nodules, intracranial hemorrhage, and other conditions on medical imaging.

20

Overview

Qure.ai is a healthcare AI company that develops imaging analysis tools for radiologists, pulmonologists, and emergency physicians. Its solutions are designed to assist in the detection and management of lung nodules, intracranial hemorrhage, and other critical conditions, with a focus on improving early diagnosis and treatment.

The Clinical Challenge Qure.ai Addresses

Lung cancer remains one of the most common and deadly cancers worldwide, and early detection is critical for improving patient outcomes. However, identifying subtle lung nodules on chest imaging can be challenging, especially in high-volume reading environments where radiologists face fatigue and time constraints. Similarly, conditions like intracranial hemorrhage require immediate attention, and every minute counts. Qure.ai aims to address these challenges by providing AI-powered tools that act as an additional set of eyes for clinicians, flagging potential abnormalities that may require further evaluation.

Core Technology and Product Suite

Qure.ai's flagship products include qXR for chest X-ray analysis and qCT for CT imaging. These tools are designed to detect a range of findings, including lung nodules, pneumothorax, pleural effusion, and intracranial hemorrhage. The algorithms are trained on large datasets and have been validated in multicenter studies. For instance, a publication on missed and mislabeled chest radiography findings reported up to 96% sensitivity and 100% specificity for the qXR algorithm in detecting pneumothoraces and pleural effusions. Qure.ai has received 26 FDA-cleared indications for its products, underscoring its regulatory compliance and clinical utility.

Integration into Clinical Workflows

Qure.ai emphasizes seamless integration into existing clinical workflows. The tools are designed to work within real-world settings, providing alerts and annotations that help clinicians prioritize cases and make informed decisions. According to a cardiothoracic radiologist at University Hospitals Cleveland Medical Center, AI serves as an additional set of eyes, enhancing detection by flagging lung nodules that may require further evaluation. This approach may aid in identifying more nodules, supporting patient care and enabling evaluation of the broader impact of medical imaging AI. A clinical trial is underway to assess how many patients require follow-up CT scans, biopsies, and how many more lung cancer cases are diagnosed earlier using AI.

Validation and Clinical Evidence

Qure.ai's solutions have been validated in multiple studies and real-world collaborations. A radiologist at Massachusetts General Hospital noted extensive validation of the qER solution for intracranial hemorrhage, highlighting its potential to improve care. Another radiologist at Sinai Chicago praised qXR's ability to detect subtle nodules without creating reader fatigue, and qCT's annotation tools, refined in collaboration with Qure's product engineers, for supporting both radiologists and referring physicians. These testimonials reflect the company's focus on designing solutions with end users and patients in mind.

Partnerships and Market Presence

Qure.ai has partnered with Microsoft to increase access to its lung cancer detection and management suite in the U.S. This collaboration aims to expand the reach of its AI tools and support healthcare providers in improving early detection. The company reports that its solutions have impacted over 45 million lives to date and has raised $130 million in capital. These figures indicate significant adoption and investment in its mission to provide accessible, affordable, and timely assistance to healthcare professionals.

The Future of AI in Medical Imaging

As healthcare systems continue to adopt AI technologies, Qure.ai is positioned to play a role in transforming lung cancer surveillance and critical care imaging. The ongoing clinical trial and partnerships with major healthcare organizations suggest a commitment to evidence generation and real-world validation. While challenges remain, such as integration with diverse PACS systems and varying clinical workflows, Qure.ai's focus on regulatory clearance and clinical evidence may help it navigate these hurdles. For radiologists and other clinicians, Qure.ai offers a tool that could augment their expertise and potentially improve patient outcomes.

Core features

  • Supports the lung nodule pathway from identification to treatment
  • Flags lung nodules on chest imaging for further evaluation
  • Detects intracranial hemorrhage on head CT
  • Achieves up to 96% sensitivity and 100% specificity for pneumothorax and pleural effusion on chest X-ray
  • 26 FDA-cleared indications
  • Integrates into real-world clinical workflows

Use cases

  1. 1Early detection of lung cancer through nodule identification on chest imaging
  2. 2Triage of intracranial hemorrhage in emergency settings
  3. 3Detection of pneumothorax and pleural effusion on chest radiography
  4. 4Clinical trials evaluating AI impact on lung cancer surveillance
  5. 5Supporting radiologists in high-volume reading environments

Strengths and things to check

Strengths

  • FDA-cleared for multiple clinical indications
  • Validated in multicenter studies with high sensitivity and specificity
  • Designed to integrate into existing workflows without adding reader fatigue
  • Backed by partnerships with major healthcare organizations

Things to check

  • Clinical validation is ongoing; real-world performance may vary
  • Adoption requires integration with existing PACS and clinical workflows
  • Availability may be limited to certain healthcare settings

Pricing

Subscription pricing is not listed.

Basic information

Website
qure.ai
Added
Oct 10, 2026
Platforms
Web
Chinese & English
Not marked
API
Marked as supported
Self-hosting
Not marked
Best for
Radiologists, pulmonologists, and emergency physicians in U.S. healthcare settings.
Information updated
Oct 16, 2026
Website status
Checking
Corrections · Privacy · Data requests?
Contact us

Features, pricing and availability may change. Always verify details on the official website. Maintained by steven · Last updated Oct 16, 2026 →

Related tools

All categories

Wysa

Enterprise Grade

Wysa is an AI-powered mental health support platform that offers safe, clinically backed care for individuals, teams, and health systems. It provides self-help, guided referral, and between-session support through an always-available, anonymous chat interface.

Enterprise GradeAPI Available
60
Free Tier
View details